Albert Wiegman

15.2k total citations · 2 hit papers
144 papers, 5.1k citations indexed

About

Albert Wiegman is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Albert Wiegman has authored 144 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Surgery, 50 papers in Endocrinology, Diabetes and Metabolism and 39 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Albert Wiegman's work include Lipoproteins and Cardiovascular Health (124 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (48 papers) and Cancer, Lipids, and Metabolism (33 papers). Albert Wiegman is often cited by papers focused on Lipoproteins and Cardiovascular Health (124 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (48 papers) and Cancer, Lipids, and Metabolism (33 papers). Albert Wiegman collaborates with scholars based in Netherlands, United States and Canada. Albert Wiegman's co-authors include John J.P. Kastelein, Barbara A. Hutten, Eric de Groot, Jessica Rodenburg, D. Meeike Kusters, Eric J.G. Sijbrands, H. D. Bakker, Ilse K. Luirink, Frits A. Wijburg and G. Kees Hovingh and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Albert Wiegman

139 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia

2019 389 citations Ilse K. Luirink, Albert Wiegman et al. New England Journal of Medicine profile →
Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome

2014 308 citations D. Meeike Kusters, Joep C. Defesche et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Albert Wiegman Netherlands	37	3.8k	1.8k	1.7k	944	676	144	5.1k
Anne Langsted Denmark	33	3.0k 0.8×	1.9k 1.0×	1.5k 0.9×	937 1.0×	219 0.3×	77	4.4k
Jeanine E. Roeters van Lennep Netherlands	33	1.6k 0.4×	885 0.5×	1.2k 0.7×	482 0.5×	402 0.6×	182	3.8k
Helmut G. Schrott United States	32	2.7k 0.7×	2.5k 1.4×	1.3k 0.8×	785 0.8×	557 0.8×	59	5.4k
C Pollicino Australia	6	3.5k 0.9×	1.6k 0.9×	1.3k 0.8×	852 0.9×	237 0.4×	9	5.1k
Gabriele Riccardi Italy	14	3.0k 0.8×	1.6k 0.9×	1.5k 0.9×	583 0.6×	285 0.4×	20	4.5k
Claude Gagné Canada	34	2.6k 0.7×	1.9k 1.0×	1.1k 0.7×	858 0.9×	262 0.4×	77	4.0k
T. Sourjina Australia	8	3.6k 1.0×	1.6k 0.9×	1.3k 0.8×	929 1.0×	236 0.3×	9	5.3k
Carl E. Orringer United States	24	2.4k 0.6×	1.2k 0.6×	1.0k 0.6×	415 0.4×	214 0.3×	55	3.7k
Anette Varbo Denmark	34	3.5k 0.9×	3.2k 1.7×	1.9k 1.2×	1.2k 1.3×	308 0.5×	57	5.8k
Christina Reith United Kingdom	15	3.8k 1.0×	1.6k 0.9×	1.3k 0.8×	702 0.7×	232 0.3×	30	5.4k

Countries citing papers authored by Albert Wiegman

Since Specialization

Citations

This map shows the geographic impact of Albert Wiegman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert Wiegman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert Wiegman more than expected).

Fields of papers citing papers by Albert Wiegman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albert Wiegman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert Wiegman. The network helps show where Albert Wiegman may publish in the future.

Co-authorship network of co-authors of Albert Wiegman

This figure shows the co-authorship network connecting the top 25 collaborators of Albert Wiegman. A scholar is included among the top collaborators of Albert Wiegman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albert Wiegman. Albert Wiegman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brands, Marion M., Ilse J.M. Nijhuis, G.H. Hofsteenge, et al.. (2024). Breaking the chains of lipoprotein lipase deficiency: A pediatric perspective on the efficacy and safety of Volanesorsen. Molecular Genetics and Metabolism. 142(1). 108347–108347. 2 indexed citations

Raal, Frederick J., Robert A. Hegele, Andrea Ruzza, et al.. (2024). Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arteriosclerosis Thrombosis and Vascular Biology. 44(5). 1156–1164. 9 indexed citations

Reeskamp, Laurens F., G. Kees Hovingh, R. Nils Planken, et al.. (2024). Beyond early LDL cholesterol lowering to prevent coronary atherosclerosis in familial hypercholesterolaemia. European Journal of Preventive Cardiology. 31(7). 892–900. 11 indexed citations

Santos, Raúl D., Albert Wiegman, Sonia Caprio, et al.. (2024). Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia. JAMA Pediatrics. 178(3). 283–283. 11 indexed citations

Wiegman, Albert, et al.. (2024). The association between lipoprotein(a) levels and ischemic stroke in children: A case–control study. Pediatric Blood & Cancer. 71(10). e31236–e31236.

Wiegman, Albert, Susanne Greber‐Platzer, Shazia Ali, et al.. (2023). Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia. Circulation. 149(5). 343–353. 41 indexed citations

Corpeleijn, Willemijn E., Wouter J. de Waal, Henk S. Schipper, & Albert Wiegman. (2023). Dyslipidaemia as a target for atherosclerotic cardiovascular disease prevention in children with type 1 diabetes: lessons learned from familial hypercholesterolaemia. Diabetologia. 67(1). 19–26. 5 indexed citations

Reeskamp, Laurens F., R. Nils Planken, James K. Min, et al.. (2023). Lifetime exposure to high LDL cholesterol in familial hypercholesterolemia causes coronary atherosclerosis in young adults: The cheetah trial. Atherosclerosis. 379. S54–S54. 1 indexed citations

Santos, Raúl D., Albert Wiegman, Sonia Caprio, et al.. (2023). Efficacy and safety of alirocumab in children and adolescents with heterozygous familial hypercholesterolaemia inadequately controlled with statins. European Heart Journal. 44(Supplement_2). 1 indexed citations

10.

Hutten, Barbara A., Sotirios Tsimikas, Calvin Yeang, et al.. (2023). Lipoprotein(a) levels and carotid intima-media thickness in children: A 20-year follow-up study. Journal of clinical lipidology. 18(2). e290–e294. 3 indexed citations

11.

Gidding, Samuel S., Albert Wiegman, Urh Grošelj, et al.. (2022). Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations. European Journal of Preventive Cardiology. 29(18). 2301–2311. 40 indexed citations

12.

Tromp, Tycho R., M. Doortje Reijman, Albert Wiegman, et al.. (2022). Counseling couples at risk of having a child with homozygous familial hypercholesterolemia – Clinical experience and recommendations. Journal of clinical lipidology. 17(2). 291–296. 2 indexed citations

13.

Hutten, Barbara A., et al.. (2022). Intima-media thickness in treated and untreated patients with and without familial hypercholesterolemia: A systematic review and meta-analysis. Journal of clinical lipidology. 16(2). 128–142. 13 indexed citations

14.

Hutten, Barbara A., et al.. (2022). Lipoprotein(a) levels in children with suspected familial hypercholesterolaemia: a cross-sectional study. European Heart Journal. 44(16). 1421–1428. 14 indexed citations

15.

Reeskamp, Laurens F., Nick S. Nurmohamed, Michiel J. Bom, et al.. (2021). Marked plaque regression in homozygous familial hypercholesterolemia. Atherosclerosis. 327. 13–17. 44 indexed citations

16.

Wiegman, Albert, Miranda Langendam, Jeffrey Kroon, et al.. (2021). Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. European Journal of Preventive Cardiology. 29(5). 779–792. 87 indexed citations

17.

Futema, Marta, Uma Ramaswami, Lukáš Tichý, et al.. (2021). Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis. 319. 108–117. 19 indexed citations

18.

Santos, Raúl D., Andrea Ruzza, G. Kees Hovingh, et al.. (2020). Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. New England Journal of Medicine. 383(14). 1317–1327. 115 indexed citations

19.

Strijkers, Gustav J., Wouter V. Potters, Ilse K. Luirink, et al.. (2018). Regional assessment of carotid artery pulse wave velocity using compressed sensing accelerated high temporal resolution 2D CINE phase contrast cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance. 20(1). 86–86. 17 indexed citations

20.

Braamskamp, Marjet J.A.M., D. Meeike Kusters, Hans J. Avis, et al.. (2013). Abstract 17837: Patients With Familial Hypercholesterolemia Who Initiated Statin Treatment In Childhood Are At Lower Risk For Chd Then Their Affected Parents. Circulation. 128. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact